<DOC>
	<DOC>NCT01188863</DOC>
	<brief_summary>This protocol is intended to compare the effects of both a solid (tablet) and liquid oral dosage form of LX4211 in subjects with type 2 diabetes mellitus.</brief_summary>
	<brief_title>Study of Two Oral Formulations of LX4211 in Patients With Type 2 Diabetes Mellitus</brief_title>
	<detailed_description />
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<criteria>Adults aged 18 to 65 years of age Males and females of nonchildbearing potential Diagnosis of type 2 diabetes mellitus for at least 6 months prior to screening Fasting plasma glucose ≤240 mg/dL Body mass index &lt;42 kg/sq m HbA1c of 711% Cpeptide of ≥1.0 ng/mL Ability to provide written informed consent History of type 1 diabetes mellitus, diabetic ketoacidosis, hyperosmolar nonketonic syndrome, incontinence, or nocturia Current use of any blood glucoselowering agent other than metformin Exposure to insulin, thiazide, or loop diuretics within 4 weeks prior to screening History of HIV, Hepatitis B, or Hepatitis C Surgery within 6 months of screening Donation or loss of &gt;400 mL of blood or blood product within 8 weeks prior to start of study Use of proteins or antibodies within 12 weeks prior to screening. (Flu shots are allowed.) Exposure to any investigational agent or participation in an investigational trial within 30 days of the start of the study History of drug or alcohol abuse within 12 months prior to screening.</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>65 Years</maximum_age>
	<verification_date>March 2011</verification_date>
</DOC>